VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
VACCINEX, INC.
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $3.22M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2024
Gross margin
–
Operating margin
-3117.3%+3004.1 pts over 5 years
Net margin
-3100.5%+2991.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.4% | -12.6% | +2.8% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | – | 182.8% | – | |
| Return on assets | – | -239.3% | -598.5% | |
| Current ratio | – | 0.58 | 0.50 | |
| Debt to equity | – | – | – | |
| Interest coverage | – | – | -9367.5× | |
| Capex to revenue | – | 14.9% | 3.7% | |
| Diluted shares | – | 0M | 2M |
Where the cash went
Fiscal 2020 to 2024, five years combined
Vaccinex generated $110.58M from operations and spent $510.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$110.58M
Used
$510.00K
Capital expenditure$510.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2486.7%
×Asset turnover0.08×
×Equity multiplier-1.12×
=Return on equity, FY2021233.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2021 | -2486.7% | 0.08× | -1.12× | 233.6% |
| FY2020 | -4616.2% | 0.08× | -0.31× | 109.3% |
| FY2019 | -6092.4% | 0.04× | -0.76× | 182.8% |
| FY2018 | -4077.1% | 0.05× | -0.21× | 44.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
3of 8 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero-$18.63M
- Cash generatingOperating cash flow above zero-$16.19M
- Return on assets improvedROA up on the prior year-253.9% → -513.2%
- Earnings backed by cashOperating cash flow above net income-$16.19M vs -$18.63M
- Less leverageLong-term debt to assets fell0.7% → 0.0%
- Better liquidityCurrent ratio rose0.57 → 0.50
- No dilutionShare count did not rise0M → 2M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.07 → 0.17